NCT01307046

MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 336 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	MK-0954A	Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
DRUG	Losartan	Tablet containing losartan potassium (100 mg), once daily
DRUG	Placebo to MK-0954A	Placebo tablet to match MK-0954A, once daily
DRUG	Placebo to losartan 100 mg	Placebo tablet to match losartan 100 mg, once daily
DRUG	Placebo to losartan 50 mg	Placebo tablet to match losartan 50 mg, once daily

Timeline

• Start date: 2011-03-29
• Primary completion: 2012-02-07
• Completion: 2012-02-07
• First posted: 2011-03-02
• Last updated: 2024-05-17
• Results posted: 2013-03-22